Water Street Healthcare Partners

Water Street was founded in 2005 by Timothy Dugan, Rob Womsley, and additional partners who previously worked together at One Equity Partners, the private equity division of JPMorgan Chase. Dugan and Womsley brought experience executing control investments across healthcare subsectors and recruited a team that includes former operating executives from Baxter, Cardinal Health, and GE Healthcare. The firm remains led by its original founding partners.

Water Street focuses on control buyouts in middle-market healthcare, with a strong emphasis on corporate carve-outs from larger medical companies and founder-owned businesses seeking a transition. The firm typically invests $50 million to $500 million of equity per deal across medical devices, pharmaceutical services, diagnostics, and specialty distribution. It avoids minority positions and prefers to partner with an identified management team before closing a transaction.

Yes, Water Street has invested in European healthcare companies, including its high-profile public-to-private acquisition of Fagron, a global pharmaceutical compounding business headquartered in the Netherlands. The firm evaluates opportunities across the US and Western Europe, leveraging a network of operating partners with cross-border experience to manage and scale international portfolio companies.

Water Street structures some of its investment vehicles with extended, flexible holding periods rather than the standard 5-to-7-year private equity fund life. This permanent or long-dated capital approach allows the firm to hold healthcare assets for a decade or longer, aligning with the extended timelines required to complete FDA cycles, scale clinical infrastructure, and realize regulatory-driven market consolidation.

Notable portfolio companies have included Fagron (pharmaceutical compounding), Aspen Surgical (medical products), TIDI Products (acute-care consumables), and Breg (orthopedic bracing), which was later sold to Orthofix. The firm has also backed Pharming Group, a rare-disease biopharmaceutical company that completed a public listing. Water Street tends to build platforms through multiple add-on acquisitions under a single holding.

Water Street is a pure-play healthcare investor — every partner, operating advisor, and dollar under management is dedicated to the sector. This focus allows the firm to originate corporate carve-outs directly from large medical companies, internally incubate new platforms, and assess regulatory risk with in-house expertise that generalist firms typically outsource to consultants. The firm does not raise diversified general-buyout funds alongside its healthcare vehicles.

Water Street raises committed capital in discrete fund vehicles, but its philosophy ties each fundraise to a specific healthcare investment thesis rather than a generic capital-gathering cycle. This approach means some funds target a single platform buildout, while others cover multiple investments in a defined subsector such as medical products or pharmaceutical services.